Comparison of Overall Survival Associated with Lenalidomide plus Dexamethasone and Bortezomib plus Dexamethasone Among Relapsed / Refractory Multiple Myeloma Patients: A Matched Analysis of Real World and Clinical Trial Populations

被引：0
|
作者：
Nooka, Ajay
Voorhees, Peter M.
Kumar, Shaji K.
Mehra, Maneesha
Lam, Annette
Slavcev, Mary
Potluri, Ravi
Dasgupta, Anandaroop
机构：
来源：
BLOOD | 2017年 / 130卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3094
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed/Refractory Multiple Myeloma (RRMM) Patients: An Update of Overall Survival in Castor
    Lentzsch, Suzanne
    Quach, Hang
    Chanan-Khan, Asher A.
    Horvath, Noemi
    Capra, Marcelo
    Ovilla, Roberto
    Jo, Jae-Cheol
    Shin, Ho-Jin
    Thiyagarajah, Piruntha
    Amin, Himal
    Casneuf, Tineke
    Sonneveld, Pieter
    Schecter, Jordan
    Hungria, Vania T. M.
    BLOOD, 2017, 130
  • [32] Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma
    Kumar, Shaji
    Moreau, Philippe
    Hari, Parameswaran
    Mateos, Maria-Victoria
    Ludwig, Heinz
    Shustik, Chaim
    Masszi, Tamas
    Spencer, Andrew
    Hajek, Roman
    Romeril, Kenneth
    Avivi, Irit
    Liberati, Anna M.
    Minnema, Monique C.
    Einsele, Hermann
    Lonial, Sagar
    Berg, Deborah
    Lin, Jianchang
    Gupta, Neeraj
    Esseltine, Dixie-Lee
    Richardson, Paul G.
    BRITISH JOURNAL OF HAEMATOLOGY, 2017, 178 (04) : 571 - 582
  • [33] ECONOMIC EVALUATION OF CARFILZOMIB plus LENALIDOMIDE plus DEXAMETHASONE (KRD) VS LENALIDOMIDE plus DEXAMETHASONE (RD) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (R/RMM)
    Fonseca, R.
    Panjabi, S.
    Campioni, M.
    Giannopoulou, A.
    Benedict, A.
    Houisse, I.
    Aggarwal, S.
    Jakubowiak, A.
    HAEMATOLOGICA, 2016, 101 : 526 - 526
  • [34] Cost-effectiveness of carfilzomib plus dexamethasone compared with bortezomib plus dexamethasone for patients with relapsed or refractory multiple myeloma in the United States
    Jakubowiak, Andrzej J.
    Houisse, Ivan
    Majer, Istvan
    Benedict, Agnes
    Campioni, Marco
    Panjabi, Sumeet
    Ailawadhi, Sikander
    EXPERT REVIEW OF HEMATOLOGY, 2017, 10 (12) : 1107 - 1119
  • [35] EXPANDED ACCESS PROGRAM (EAP) FOR LENALIDOMIDE PLUS DEXAMETHASONE IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA
    Palumbo, A.
    Gay, F.
    Buda, G.
    Guglielmelli, T.
    Perrone, G.
    Corradini, P.
    Benedetti, F.
    Offidani, M.
    Rossi, D.
    Gozzetti, A.
    Catalano, L.
    Canepa, L.
    Di Raimondo, F.
    Patriarca, F.
    Petrucci, M. T.
    Di Renzo, N.
    Galli, M.
    Cavallo, F.
    Bringhen, S.
    Boccadoro, M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 257 - 257
  • [36] BORTEZOMIB PLUS DEXAMETHASONE IN COMBINATION WITH MELPHALAN OR CYCLOPHOSPHAMIDE IN THE TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA
    Tsirigotis, P.
    Girkas, K. G.
    Giannopoulou, V.
    Chondropoulos, S.
    Ioannidou, E.
    Papaxoinis, G.
    Pappa, V.
    Vasilatou, D.
    Dimoula, K.
    Kapodistrias, N.
    Papageorgiou, E.
    Economopoulos, T.
    Dervenoulas, J.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 436 - 436
  • [37] Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma
    Bahlis, Nizar J.
    Sutherland, Heather
    White, Darrell
    Sebag, Michael
    Lentzsch, Suzanne
    Kotb, Rami
    Venner, Christopher P.
    Gasparetto, Cristina
    Del Col, Aldo
    Neri, Paola
    Reece, Donna
    Kauffman, Michael
    Shacham, Sharon
    Unger, T. J.
    Jeha, Jacqueline
    Saint-Martin, Jean-Richard
    Shah, Jatin
    Chen, Christine
    BLOOD, 2018, 132 (24) : 2546 - 2554
  • [38] ELOQUENT-3 Trial: Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma Final Overall Survival Analysis
    Raab, Marc-Steffen
    Dimopoulos, Meletios
    Dytfeld, Dominik
    Grosicki, Sebastian
    Moreau, Philippe
    Takezako, Naoki
    Hori, Mitsuo
    Leleu, Xavier
    Leblanc, Richard
    Suzuki, Kenshi
    Richardson, Paul G.
    Mckiver, Mihaela Popa
    Jou, Ying-Ming
    Yao, David
    Das, Prianka
    San-Miguel, Jesus
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 174 - 174
  • [39] Economic evaluation of carfilzomib plus lenalidomide plus dexamethasone (KRd) vs. lenalidomide plus dexamethasone (Rd) in relapsed or refractory multiple myeloma (R/RMM).
    Jakubowiak, Andrzej J.
    Benedict, Agnes
    Panjabi, Sumeet
    Houisse, Ivan
    Campioni, Marco
    Giannopoulou, Andromachi
    Aggarwal, Sanjay
    Fonseca, Rafael
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [40] Phase 1 open-label study of panobinostat, lenalidomide, bortezomib plus dexamethasone in relapsed and relapsed/refractory multiple myeloma
    Laubach, Jacob P.
    Tuchman, Sascha A.
    Rosenblatt, Jacalyn M.
    Mitsiades, Constantine S.
    Colson, Kathleen
    Masone, Kelly
    Warren, Diane
    Redd, Robert A.
    Grayson, Dena
    Richardson, Paul G.
    BLOOD CANCER JOURNAL, 2021, 11 (02)
12345